• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Nervous Pooch? There's a Drug for That

Zoetis is not averse to a little noise as investors, analysts take notice.
By ANDERS KEITZ Sep 09, 2016 | 02:30 PM EDT
Stocks quotes in this article: PFE, ZTS, VRX, BAYRY, MRK

This story has been updated to reflect the correct dosage amounts of Sileo, as provided by Zoetis. 

As the dog days of summer turn into fall, Americans continue to pamper their pets, treating them as members of the family -- which apparently includes medicating them.

The humanization of pets is fueling growth throughout the pet industry and Zoetis (ZTS) (which spun off from Pfizer (PFE) in 2013) is catching the eye of investors. Credit Suisse just added the global animal health care company to its Focus List on Tuesday. The analysts highlighted Zoetis' attractive and diverse drug portfolio, which they believe will continue to grow the company's top line ahead of the rest of its industry -- and they aren't wrong.

There's a new product that Zoetis has that could be a big boon for business: Sileo, the first and only noise aversion medicine for dogs that's been approved by the Food and Drug Administration. Zoetis launched the product in May under an exclusive agreement with Finnish company Orion. And the oral paste that works in 30 minutes arrived in time for the holiday most dogs hate: the Fourth of July. The Kelsey Canine Medical Center in Collierville, Tenn., posted a video on Twitter to demonstrating how the medicine works.

#sileo, our new #dog med to help dogs with anxiety to loud noises, works well this July 3. He's not shaking now! pic.twitter.com/gEoj9MC0F8

- Kelsey Canine (@kelseycanine) July 4, 2016

While aversion to noises like thunder and fireworks do not affect every dog, Sileo is slowly adding to Zoetis' top line.

"New products other than Apoquel, including our new companion animal vaccines, Simparcia, Synovex1, and Sileo, to name a few, added 2%," said former CFO Paul Herendeen, who went to Valeant (VRX) recently, during the second-quarter conference call.

Despite being such a small percentage of revenue for Zoetis, noise aversion is a common problem. Rivergate Veterinary Clinic's founder and medical director Dr. Peter Kross said about 25% of his canine clientele suffer from noise aversion. An online survey conducted by Harris Poll on behalf of Zoetis in November 2013 found that among 784 dog owners, one third reported that their dog suffers from noise aversion. Another study published in Applied Animal Behavior Science Journal looked at noise sensitivity in 17 dog breeds. The researchers found that of the 5,257 dogs studied, on average, about 23% were fearful of noises. So, yes, it's a pretty common problem.

Dr. Kross said Sileo was "totally" needed as vets had used Benadryl, Xanax and Valium with "mixed results." He added that the drug used in Sileo is a drug used in anesthesia for dogs, remarking that it is "not a novel drug, just a novel use for it."

Sileo costs roughly $30, depending on your vet, and the doses vary depending on the size of the dog. For a small dog less than 12 pounds there would be about 12 full doses, but for a large dog weighing about 65 pounds, there would be about two doses. But Dr. Kross did mention one limitation with Sileo: Once the package is opened, it can only be used for two weeks, which he said could be a slight issue for small dogs.

So far, Dr. Kross, whose clinic has had Sileo since August, has dispensed 10 packages, with one client already getting a refill.

Even though Zoetis does not provide revenue forecasts for this product, the company said via email that it recognizes that "there is a significant unmet need for canine noise aversion treatments, and will work to educate veterinarians about the benefits of this new product."

Now, this drug may not be for every dog, but as part of the humanization of pets trend, it could be appealing to dog owners who see their pet distressed during thunderstorms. The noise aversion drug could be a benefit for Zoetis in the longer-term as it is the only FDA-approved treatment on the market and is qualified for three years of marketing exclusivity.

The company also has Apoquel, which treats acute and chronic itching in dogs in the form of a tablet, in its pipeline and looks to be a driver of growth in the short term -- though it won't replace those pesky cones. After experiencing a supply shortage in 2015, the drug is now more widely available and has had a "very positive story" this year, says CEO Juan Ramon Alaix.

"For the first half of 2016, we have exceeded $100 million in revenue, and since May, we have been supplying Apoquel with no restrictions," Alaix said during a conference call with analysts on Aug. 3.

With revenue of $60 million for the second quarter, the drug was an "important driver" of U.S. revenue growth (up 10% for the period) and for the companion animal segment (up 13%), in terms of the global business.

Apoquel's revenue should continue to grow as Zoetis has launched the drug in regional markets such as Brazil, Japan, Mexico and Russia. The CEO added that it would also be introduced in Colombia, Peru, Singapore and Hong Kong. The company expects long-term peak revenue for Apoquel to reach $300 million. They do not provide any specifics on annual or quarterly revenue expectations.

"We have seen that most of the use of the product has been in chronic conditions. Now the effort of our people, it's really to promote the product to expand also the use of acute indications," Alaix said.

Herendeen put this opportunity in perspective for analysts during the latest quarterly conference call.

"If you take the universe of itchy dogs, over half of itchy dogs are considered acute ... the next largest group, in terms of a percentage, are the seasonal itchy dogs; and then the smallest is the chronic -- About 20% are chronic," Herendeen said.

Another drug Zoetis was touting highly was Simparica, a chewable for dogs that offers protection from fleas and ticks. Alaix said the company looks to have the product well established in the U.S. market in 2017. But the flea and tick market is pretty well saturated -- from Frontline Plus and Bayer's (BAYRY) K9 Advantix to Merck's (MRK) Bravecto and many more -- so breaking into the market (Simparica launched in the U.S. earlier this year) may be more difficult that Zoetis is anticipating.

But if investors need further convincing as to the direction of Zoetis, director Michael McAllister just purchased 2,000 shares on Sept. 6, valued at approximately $102,680.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Boston Scientific Could Be Wicked Good in This Kind of Market

Brad Ginesin
May 24, 2022 2:13 PM EDT

Here's why this healthcare stock is a potential port in the storm for investors.

2 Biotech Stocks to Own as M&A Potentially Gathers Steam

Bret Jensen
May 11, 2022 11:35 AM EDT

I like these names as stand-alone entities but they should also attract interest from larger players.

China Faces 'Tsunami' of Covid Infection That Could Swamp the System

Alex Frew McMillan
May 11, 2022 9:00 AM EDT

A new study suggests 1.55 million people could die if China abandons zero-Covid, with the intensive-care system needing 15.6 times existing capacity.

I'm Giving Dynavax Another Shot -- a Booster Shot

Bret Jensen
May 8, 2022 7:31 AM EDT

Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.

In This Environment, I'd Be More Risk Averse With Intuitive Surgical

Stephen Guilfoyle
Apr 25, 2022 10:50 AM EDT

The firm has been hurt and continues to be hurt by the effects of the pandemic.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:46 PM EDT STEPHEN GUILFOYLE

    We're Shedding Some of This Holding on Strength

    Check out the Stocks Under $10 portfolio here!
  • 11:33 AM EDT PETER TCHIR

    Thoughts Ahead of the Fed Minutes

    Recent economic and earnings issues are convincing...
  • 02:24 PM EDT PAUL PRICE

    An Interesting Chart

    I'm betting heavily that stocks will be way up aga...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login